Back to search
Recurrent Platinum Resistant Ovarian Cancer
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Recurrent Platinum Resistant Ovarian Cancer trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Recurrent Platinum Resistant Ovarian Cancer trials you may qualify forThis phase Ib trial tests the safety, side effects, and best dose of M1774 when given with ZEN-3694 in treating patients with ovarian and endometrial cancer tha…
To evaluate the efficacy and safety of B013 in patients with platinum-resistant recurrent ovarian cancer.
This phase I/Ib trial identifies the side effects and best dose of abemaciclib when given together with olaparib in treating patients with ovarian cancer that r…
The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably admi…
Ovarian carcinoma is the most lethal gynecological malignancy. Epithelial ovarian carcinoma is the gynecological malignancy with the highest mortality rate. The…
This trial is a registered, phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with platinum-resis…
This phase II/III trial studies how well pegylated liposomal doxorubicin hydrochloride with atezolizumab and/or bevacizumab work in treating patients with ovari…
This randomized phase II/III trial studies how well cediranib maleate and olaparib work when given together or separately, and compares them to standard chemoth…